679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1827764023018389504 |
|---|---|
| author | Siqing Fu Rom S Leidner Ki Chung Jiaxin Niu Ilian Tchakov Debra L Richardson Xiaoping Qing Jorge Nieva Douglas Adkins Alan L Ho Minh Phan Alexander T Pearson Marshall R Posner Lisle Nabell Stuart Wong Katerin Rojas Ari J Rosenberg Trisha Kaufmann Christopher Plescia Corinne Iacobucci Kia Katchar Klaus Orlinger Katia Schlienger David G Pfister |
| author_facet | Siqing Fu Rom S Leidner Ki Chung Jiaxin Niu Ilian Tchakov Debra L Richardson Xiaoping Qing Jorge Nieva Douglas Adkins Alan L Ho Minh Phan Alexander T Pearson Marshall R Posner Lisle Nabell Stuart Wong Katerin Rojas Ari J Rosenberg Trisha Kaufmann Christopher Plescia Corinne Iacobucci Kia Katchar Klaus Orlinger Katia Schlienger David G Pfister |
| author_sort | Siqing Fu |
| collection | DOAJ |
| first_indexed | 2024-03-11T10:58:54Z |
| format | Article |
| id | doaj.art-2139506c3af64695acf470195ba8dd75 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T10:58:54Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-2139506c3af64695acf470195ba8dd752023-11-12T15:20:07ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0679679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 studySiqing Fu0Rom S Leidner1Ki Chung2Jiaxin Niu3Ilian Tchakov4Debra L Richardson5Xiaoping Qing6Jorge Nieva7Douglas Adkins8Alan L Ho9Minh Phan10Alexander T Pearson11Marshall R Posner12Lisle Nabell13Stuart Wong14Katerin Rojas15Ari J Rosenberg16Trisha Kaufmann17Christopher Plescia18Corinne Iacobucci19Kia Katchar20Klaus Orlinger21Katia Schlienger22David G Pfister234The University of Texas – MD Anderson Cancer Center, Medical Oncology, Houston, USAAff1 grid.415286.cEarle A. Chiles Research Institute Portland OR USAAff2 grid.413319.d0000000404067499GHS Cancer Institute Spartanburg SC USA7Banner MD Anderson Cancer Center, Gilbert, AZ, USA10 Eisai, Hatfield, UK6 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA1Program in Inflammation and Autoimmunity, Hospital for Special Surgery, USA13University of Southern California, Norris Cancer Center, Los Angeles, CA, USA8Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Saint Louis, MO, USADepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA6Sarah Cannon Research Institute at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA3University of Chicago, Department of Medicine, Chicago, IL, USA5Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA7University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA14Medical College of Wisconsin, Milwaukee, WI, USA15Vall D’Hebron University Hospital, Vall D’Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain16University of Chicago Medicine, Chicago, IL, USA18Hookipa Pharma Inc., New York, NY, USA18Hookipa Pharma Inc., New York, NY, USA18Hookipa Pharma Inc., New York, NY, USA18Hookipa Pharma Inc., New York, NY, USA18Hookipa Pharma Inc., New York, NY, USA18Hookipa Pharma Inc., New York, NY, USA1Memorial Sloan Kettering Cancer Center, New York, NY, USA |
| spellingShingle | Siqing Fu Rom S Leidner Ki Chung Jiaxin Niu Ilian Tchakov Debra L Richardson Xiaoping Qing Jorge Nieva Douglas Adkins Alan L Ho Minh Phan Alexander T Pearson Marshall R Posner Lisle Nabell Stuart Wong Katerin Rojas Ari J Rosenberg Trisha Kaufmann Christopher Plescia Corinne Iacobucci Kia Katchar Klaus Orlinger Katia Schlienger David G Pfister 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study Journal for ImmunoTherapy of Cancer |
| title | 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study |
| title_full | 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study |
| title_fullStr | 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study |
| title_full_unstemmed | 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study |
| title_short | 679 Characterization of tumor specific CD8+ T cell responses in patients with recurrent/metastatic HPV16-positive head and neck cancer receiving HB-200 monotherapy as second or later line treatment in a phase 1 study |
| title_sort | 679 characterization of tumor specific cd8 t cell responses in patients with recurrent metastatic hpv16 positive head and neck cancer receiving hb 200 monotherapy as second or later line treatment in a phase 1 study |
| work_keys_str_mv | AT siqingfu 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT romsleidner 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT kichung 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT jiaxinniu 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT iliantchakov 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT debralrichardson 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT xiaopingqing 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT jorgenieva 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT douglasadkins 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT alanlho 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT minhphan 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT alexandertpearson 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT marshallrposner 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT lislenabell 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT stuartwong 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT katerinrojas 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT arijrosenberg 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT trishakaufmann 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT christopherplescia 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT corinneiacobucci 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT kiakatchar 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT klausorlinger 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT katiaschlienger 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study AT davidgpfister 679characterizationoftumorspecificcd8tcellresponsesinpatientswithrecurrentmetastatichpv16positiveheadandneckcancerreceivinghb200monotherapyassecondorlaterlinetreatmentinaphase1study |